Co-reporter:Kerry Anne Ness, Sharon L. Eddie, Stephanie Burton, Timothy Harrison, Paul Mullan, Rich Williams
Bioorganic & Medicinal Chemistry Letters 2016 Volume 26(Issue 2) pp:413-416
Publication Date(Web):15 January 2016
DOI:10.1016/j.bmcl.2015.11.101
This letter describes the design, development and SAR exploration of a novel series of small legumain inhibitors. The SAR of a new small molecule legumain inhibitor chemotype was explored and found to have improved physiochemical properties compared to previously developed inhibitors within our group. However, further development of this series was found to be limited as the SAR was observed to be relatively flat.
Co-reporter:Kerry A. Ness, Sharon L. Eddie, Catherine A. Higgins, Amy Templeman, Zenobia D’Costa, Kishore K.D. Gaddale, Samira Bouzzaoui, Linda Jordan, Dominic Janssen, Timothy Harrison, Frank Burkamp, Andrew Young, Roberta Burden, Christopher J. Scott, Paul B. Mullan, Rich Williams
Bioorganic & Medicinal Chemistry Letters 2015 Volume 25(Issue 23) pp:5642-5645
Publication Date(Web):1 December 2015
DOI:10.1016/j.bmcl.2015.10.001
This Letter describes the continued SAR exploration of small molecule Legumain inhibitors with the aim of developing a potent and selective in vitro tool compound. Work continued in this Letter explores the use of alternative P2–P3 linker units and the P3 group SAR which led to the identification of 10t, a potent, selective and cellularly active Legumain inhibitor. We also demonstrate that 10t has activity in both cancer cell viability and colony formation assays.
Co-reporter:Catherine Higgins, Samira Bouazzaoui, Kishore Gaddale, Zenobia D’Costa, Amy Templeman, Martin O’Rourke, Andrew Young, Christopher Scott, Tim Harrison, Paul Mullan, Rich Williams
Bioorganic & Medicinal Chemistry Letters 2014 Volume 24(Issue 11) pp:2521-2524
Publication Date(Web):1 June 2014
DOI:10.1016/j.bmcl.2014.04.002
This Letter describes the further development and SAR exploration of a novel series of Legumain inhibitors. Based upon a previously identified Legumain inhibitor from our group, we explored the SAR of the carbamate phenyl ring system to probe the P3 pocket of the enzyme. This led to the identification of a sub-nanomolar inhibitor of Legumain.